NetworkNewsBreaks – Lexaria Bioscience Corp.’s
Post# of 721
(Total Views: 161)
Posted On: 05/15/2019 3:49:44 PM
NetworkNewsBreaks – Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) DehydraTECH Outperforms Conventional Industry Formulations in Animal Testing
Biotechnology company and drug delivery platform innovator Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) this morning announced that animal testing has proven that its DehydraTECH(TM) technology delivers cannabinoids to the bloodstream much more quickly and effectively than conventional industry formulations. According to the update, 10 male Sprague-Dawley rats were administered CBD at 25mg per kg of bodyweight in each arm of the Lexaria animal studies. Delivery of CBD into the bloodstream was monitored over a 60-minute duration and, at two minutes, 15 minutes, and 60 minutes, DehydraTECH’s LCFA formulation delivered elevated levels of CBD in blood (showing measurable and 475% and 319% greater levels, respectively) as compared to a medium chain triglyceride (“MCT”) oil formulation. Over the entire 60-minute study, the standard DehydraTECH LCFA formulation achieved an average maximum CBD blood concentration level that was 334% more than the average maximum blood concentration level of the MCT oil formulation.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Biotechnology company and drug delivery platform innovator Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) this morning announced that animal testing has proven that its DehydraTECH(TM) technology delivers cannabinoids to the bloodstream much more quickly and effectively than conventional industry formulations. According to the update, 10 male Sprague-Dawley rats were administered CBD at 25mg per kg of bodyweight in each arm of the Lexaria animal studies. Delivery of CBD into the bloodstream was monitored over a 60-minute duration and, at two minutes, 15 minutes, and 60 minutes, DehydraTECH’s LCFA formulation delivered elevated levels of CBD in blood (showing measurable and 475% and 319% greater levels, respectively) as compared to a medium chain triglyceride (“MCT”) oil formulation. Over the entire 60-minute study, the standard DehydraTECH LCFA formulation achieved an average maximum CBD blood concentration level that was 334% more than the average maximum blood concentration level of the MCT oil formulation.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Lexaria Bioscience Corp. (LXRPD) Stock Research Links
Scroll down for more posts ▼